Abdullah Almohaizeie
Overview
Explore the profile of Abdullah Almohaizeie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
69
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Almangour T, Alkherb Z, Ghonem L, Al Musawa M, Almohaizeie A, Almuhisen S, et al.
Pharmaceuticals (Basel)
. 2025 Jan;
18(1.
PMID: 39861170
To evaluate the real-world evidence of ceftazidime-avibactam (CAZ-AVI) compared to intravenous colistin for the treatment of multidrug-resistant (MDR) infections. This is a multicenter, retrospective cohort study conducted in the period...
2.
Almangour T, Alkherb Z, Alruwaite S, Alsahli R, Alali H, Almohaizeie A, et al.
J Glob Antimicrob Resist
. 2024 May;
38():42-48.
PMID: 38821443
Background: Trimethoprim-sulfamethoxazole (TMP-SMX) has long been considered the treatment of choice for infections caused by Stenotrophomonas maltophilia. Levofloxacin has emerged as a potential option for treating these infections. This study...
3.
Almangour T, Alali H, Alkherb Z, Alowais S, Bin Saleh K, Almuhisen S, et al.
Expert Rev Anti Infect Ther
. 2024 May;
22(11):997-1005.
PMID: 38738566
Background: The aim of this study was to compare the safety and effectiveness of monotherapy versus combination therapy for the treatment of infections caused by . Methods: This retrospective, multicenter,...
4.
Almangour T, Ghonem L, Alassiri D, Aljurbua A, Al Musawa M, Alharbi A, et al.
J Infect Chemother
. 2024 Mar;
30(10):1008-1014.
PMID: 38537776
Background: Data comparing the clinical outcomes of novel β-lactam-β-lactamase inhibitors given in combination versus monotherapy for the treatment of multidrug-resistant (MDR) P. aeruginosa infections are lacking. Method: This retrospective cohort...
5.
Almaghrabi R, Macori G, Sheridan F, McCarthy S, Floss-Jones A, Fanning S, et al.
J Infect Public Health
. 2023 Dec;
17(2):299-307.
PMID: 38154433
Background: Pseudomonas aeruginosa is an opportunistic bacterium that causes serious hospital-acquired infections. To assess the risk of clinically isolated P. aeruginosa to human health, we analyzed the resistance and virulence...
6.
Alsultan A, Dasuqi S, Almohaizeie A, Aljutayli A, Aljamaan F, Omran R, et al.
J Clin Pharmacol
. 2023 Oct;
64(3):353-361.
PMID: 37862131
Obesity combined with critical illness might increase the risk of acquiring infections and hence mortality. In this patient population the pharmacokinetics of antimicrobials vary significantly, making antimicrobial dosing challenging. The...
7.
Almangour T, Ghonem L, Alassiri D, Aljurbua A, Al Musawa M, Alharbi A, et al.
Antimicrob Agents Chemother
. 2023 Jul;
67(8):e0040523.
PMID: 37404159
Ceftolozane-tazobactam (C-T) and ceftazidime-avibactam (CAZ-AVI) are two novel antimicrobials that retain activity against resistant Pseudomonas aeruginosa. The comparative effectiveness and safety of C-T versus CAZ-AVI remain unknown. A retrospective, multicenter...
8.
Alsultan A, Al Munjem M, Atiq K, Aljehani Z, Al Muqati H, Almohaizeie A, et al.
Front Pediatr
. 2023 Apr;
11:1093171.
PMID: 37063687
Introduction: Vancomycin dosing in very low birth weight (VLBW) neonates is challenging. Compared with the general neonatal population, VLBW neonates are less likely to achieve the vancomycin therapeutic targets. Current...
9.
Abouelkheir M, Almohaizeie A, Almutairi A, Almuhisen S, Alqahtani S, Alsultan A
Pediatr Neonatol
. 2022 Dec;
64(3):327-334.
PMID: 36581523
Background: Vancomycin is commonly used to treat methicillin-resistant staphylococcal infections in neonates. Consensus on its ideal dosing in neonates has not been achieved. Model-based dosing recently has evolved as an...
10.
Abanamy R, Alsaud A, Alabdulali R, Alsobaie M, Alalwan B, AlJohani S, et al.
IJID Reg
. 2022 Aug;
4:152-156.
PMID: 35941863
Background: Mucormycosis is a life-threatening fungal infection with variable epidemiology between countries. Limited data are available locally; we aim to describe the clinical spectrum and outcome of mucormycosis in Saudi...